Immunome
NASDAQ: IMNMExton, US · Delaware corporation · 273 employees on LinkedIn · 3 known investors
Find your way into Immunome
652 people in our graph share verified history with the Immunome team — schools, employers, funds. One of them is your warm intro.
Immunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.
Founders & leadership
Investors · 3
Funding
SEC filings, press & company announcements$69.3M disclosed across 10 of 11 rounds · 2012–2025
- Undisclosed amountpublic offeringJan 2025Source ↗
▶$27MraisedMay 2021 · 47 investors · BiotechnologyRule 506(b)
- John LaMattinaDirector
- Dennis H GiesingExecutive Officer
- Corleen RocheExecutive Officer
- Michael RappDirector
- Michael J MorinExecutive Officer
- Purnanand SarmaExecutive Officer, Director
- Richard BaronDirector
- Michael D WidlitzDirector
- Michael LefenfeldDirector
- Philip WagenheimDirector
- Sandra G StonemanExecutive Officer
- Offering amount
- $27M
- Amount sold
- $27M
- Sales commissions
- $410K
- Proceeds to insiders
- $1.3M
- Placement agents
- Ladenburg Thalmann & Co. Inc.
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11MraisedJun 2020 · 49 investors · BiotechnologyRule 506(b)
- Purnanand SarmaExecutive Officer, Director
- Michael LefenfeldDirector
- Michael J MorinExecutive Officer, Director
- John LaMattinaDirector
- I Wistar MorrisDirector
- Michael D RapoportDirector
- Philip R WagenheimDirector
- Michael D WidlitzDirector
- Offering amount
- $11M
- Amount sold
- $11M
- Proceeds to insiders
- $330K
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9.3MraisedNov 2019 · 35 investors · BiotechnologyRule 506(b)
- Michael D. RapoportDirector
- David KutcherExecutive Officer
- I. Wistar MorrisDirector
- Michael LefenfeldDirector
- John LaMattinaDirector
- Philip R. WagenheimDirector
- Michael D. WidlitzDirector
- Michael J. MorinExecutive Officer, Director
- Purnanand SarmaExecutive Officer, Director
- Scott DessainExecutive Officer
- Offering amount
- $16.8M
- Amount sold
- $9.3M
- Proceeds to insiders
- $500K
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.5MraisedMay 2019 · 27 investors · BiotechnologyRule 506(b)
- Michael D. WidlitzDirector
- Michael J. MorinExecutive Officer, Director
- Michael D. RapoportDirector
- David KutcherExecutive Officer
- Michael LefenfeldDirector
- Scott DessainExecutive Officer
- Philip R. WagenheimExecutive Officer, Director
- John LaMattinaDirector
- I. Wistar MorrisDirector
- Offering amount
- $6.5M
- Amount sold
- $6.5M
- Proceeds to insiders
- $315K
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MraisedMay 2017 · 48 investors · BiotechnologyRule 506(b)
- Gregory HarrimanDirector
- Michael D. RapoportDirector
- Philip R. WagenheimExecutive Officer, Director
- Michael J. MorinExecutive Officer, Director
- David KutcherExecutive Officer
- Michael D. WidlitzDirector
- I. Wistar MorrisDirector
- Scott DessainExecutive Officer
- Offering amount
- $5M
- Amount sold
- $5M
- Proceeds to insiders
- $315K
- First sale
- May 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.1MraisedJul 2016 · 27 investors · BiotechnologyRule 506(b)
- Gregory HarrimanDirector
- Michael D. RapoportDirector
- Michael J. MorinExecutive Officer
- Philip R. WagenheimDirector
- I. Wistar MorrisDirector
- Jane H. HollingsworthExecutive Officer, Director
- Michael D. WidlitzDirector
- Offering amount
- $12M
- Amount sold
- $5.1M
- Proceeds to insiders
- $756K
- First sale
- Jul 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.6MraisedDec 2015 · 18 investors · BiotechnologyRule 506(b)
- Jane H. HollingsworthExecutive Officer, Director
- Joel SussmanExecutive Officer
- I. Wistar MorrisDirector
- Michael D. WidlitzDirector
- Michael D. RapoportDirector
- Philip R. WagenheimDirector
- Gregory HarrimanDirector
- Offering amount
- $8.5M
- Amount sold
- $3.6M
- Proceeds to insiders
- $472K
- First sale
- Nov 2015
- Incorporated
- Corporation, Pennsylvania
- Federal exemptions
- 06b
▶$892.5KraisedApr 2015 · 17 investors · PharmaceuticalsRule 506(b)
- Scott K. DessainExecutive Officer
- Gregory HarrimanDirector
- Joan LauExecutive Officer
- I. Wistar MorrisDirector
- Joel SussmanExecutive Officer
- Jane H. HollingsworthExecutive Officer, Director
- Offering amount
- $1.1M
- Amount sold
- $892.5K
- Minimum investment
- $5K
- Proceeds to insiders
- $162.5K
- First sale
- Sep 2014
- Incorporated
- Corporation, Pennsylvania
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Company profile
researched Aug 2026Immunome is a clinical-stage oncology company focused on discovering and developing targeted cancer therapies for indications with high unmet need. Its stated mission is to improve outcomes for cancer patients by advancing a portfolio of first-in-class and best-in-class therapeutic candidates, with an emphasis on antibody-drug conjugates (ADCs).
The company's most advanced programs are varegacestat (formerly AL102), a late-clinical-stage gamma secretase inhibitor for desmoid tumors; IM-1021, a ROR1-targeted ADC in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand that received IND clearance in the first quarter of 2025. Preclinical candidates include IM-1617, IM-1340 and IM-1335, all ADCs directed at undisclosed targets expressed in multiple solid tumors. Immunome states that its team members previously held key roles in the design, development and commercialization of ADCs that are now standard of care in several cancer indications.
Traction
As of 2025, Immunome reported a late-clinical-stage program (varegacestat) in desmoid tumors, a Phase 1 trial of IM-1021, IND clearance for IM-3050 in Q1 2025, and three additional ADC candidates in preclinical development.
▸Full profile — market position, technology, go-to-market
Market position
The company positions itself around pursuing differentiated and previously difficult targets, holistic optimization of all ADC components rather than individual elements, and a team with prior experience developing and commercializing approved ADCs.
Technology
Immunome's preclinical discovery work centers on antibody-drug conjugates, using a systematic, data-driven process in which each ADC component — antibody, linker and payload — is optimized both individually and in combination for efficacy, tolerability and clinical differentiation. Beyond ADCs, the pipeline includes a small-molecule gamma secretase inhibitor (varegacestat) and a FAP-targeted radioligand (IM-3050).
Go-to-market
Cancer patients, with initial programs addressing desmoid tumors and solid tumors expressing targets such as ROR1 and FAP.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Competitors · 4
by search overlap
Companies competing with Immunome for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 1
launches, deals, and filingsIM-3050, Immunome's FAP-targeted radioligand candidate, received IND clearance in the first quarter of 2025.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structureIn the news
Immunome (IMNM) Starts IM 3050 Trial As Valuation Questions Come Into View - Simply Wall St Newssimplywall.st · Aug 2026▸Research sources · 1
primary sources listed
- Immunomeimmunome.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Immunome do?
- Clinical-stage oncology company developing antibody-drug conjugates and other targeted cancer therapies.
- Who founded Immunome?
- Immunome was founded by Scott K. Dessain.
- Who are Immunome's investors?
- Immunome's investors include Evolution VC Partners, Militia Hill Ventures, T. Rowe Price.
- How much funding has Immunome raised?
- Immunome has disclosed $69.3M raised across 10 of its 11 known rounds.
- Where is Immunome headquartered?
- Immunome is headquartered in Exton, US.